AI Terminal
CRANEWARE PLC
Transaction in Own Shares • Apr 16, 2024
7581_rns_2024-04-16_d550c3a8-9b2f-48d4-bb2e-f3757d5a47a3.html
Transaction in Own Shares
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6339K
Craneware plc
16 April 2024
Craneware plc
("Craneware" or the "Company" or the "Group")
Extension of share buyback programme
16 April 2024 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce its decision to extend the share buyback programme, which was due to expire on 17 April 2024, for a further three months to 17 July 2024, under the same terms as previously announced.
For further information, please contact:
| Craneware plc | +44 (0)131 550 3100 |
| Keith Neilson, CEO | |
| Craig Preston, CFO | |
| Alma Strategic Communications | +44 (0)20 3405 0205 |
| Caroline Forde, Kinvara Verdon | [email protected] |
| Peel Hunt (NOMAD and Joint Broker) | +44 (0)20 7418 8900 |
| Neil Patel, Paul Gillam, Kate Bannatyne | |
| Investec Bank PLC (Joint Broker) | +44 (0)20 7597 5970 |
| Patrick Robb, Cameron MacRitchie | |
| Berenberg (Joint Broker) | +44 (0)20 3207 7800 |
| Mark Whitmore, Richard Andrews, Dan Gee-Summons |
About Craneware
The Craneware Group (AIM:CRW.L), the market leader in automated value cycle solutions, including 340B management, collaborates with U.S. healthcare providers to plan, execute, and monitor operational and financial performance so they can continue to deliver quality care to their communities. Customers choose The Craneware Group's Trisus data and applications platform as their key to navigating the journey to financially sustainable value-based care. Trisus combines revenue integrity, cost management, 340B performance, and decision enablement into a single, SaaS-based platform. The Craneware Group - transforming the business of healthcare.
Learn more at www.thecranewaregroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSIAMMTMTBBBTI